While Gilead Sciences, Inc.’s Phase III TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) technically met its primary endpoint in third-line HR-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC), public statements by the company and a lack of details about progression-free survival (PFS) and overall survival (OS) data raised uncertainty about whether they would be enough to drive commercial adoption.
Gilead announced the study results on 7 March, but did not disclose any data, saying instead that the trial met...
Welcome to Scrip
Create an account to read this article
Already a subscriber?